🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchPemvidutide Phase 2 — NAFLD endpoints Page 4

Pemvidutide Phase 2 — NAFLD endpoints

MASHdoc_SA Sat, Jun 6, 2026 at 4:01 AM 20 replies 520 viewsPage 4 of 4
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
Jun 7, 2026 at 9:16 AM#16
claudia_zurich said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Second this.

6 6FitDadDave, RunnerRach, TrialNerd_Beth and 3 others
Reply Quote Save Share Report
marco_milano
Member
345
1,456
Jul 2024
Milan, IT
Jun 7, 2026 at 1:18 PM#17
Dr.PathRoch said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

5 5alex_tucson, kevin_tulsa, Dr.PainCLE and 2 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jun 7, 2026 at 5:20 PM#18
Dr.PathRoch said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Fair, and it stops being fair at the extremes. The middle of the range is well understood; the ends are where the honest answer is that nobody knows.

4 4AussieAnna, BethLabQueen, ChrisMacros and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jun 7, 2026 at 9:22 PM#19
Dr.PathRoch said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.

Last edited: Jun 8, 2026 at 12:22 AM
3 3Dr.CardioMD, EndoResFellow, PharmacoVig_BOS
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 1:24 AM#20

Moderator note: a couple of off-topic posts removed. Carry on.

31 6PurityPaulOR, MaxMetOK, MounjBrad and 28 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register